Infection and Vaccines
Addressing infectious diseases
AstraZeneca is committed to developing and implementing scientific advancement in infection and vaccines.
We work to protect patients against the burden of influenza and bacterial infections, particularly those resistant to current antibiotics.
In Europe, antimicrobial resistance results in 25,000 deaths from hospital-acquired infections, while there are 3-5 million severe cases of influenza each year worldwide.
Demand for health interventions to address these burdens of disease remains high and, through working with the wider infection community, AstraZeneca aims to translate science into solutions to address global challenges faced in these disease areas.
Our focus on infectious diseases
Infectious diseases are the second-leading cause of death worldwide, after heart disease, and are responsible for more deaths annually than cancer.
Antimicrobial resistance (AMR)
AMR is a major public health threat. As bacteria develop resistance to current antibiotics, deadly infections could, again, become uncontrollable.
Seasonal influenza is a serious public health problem that causes severe illness and death in high-risk populations.
In Europe alone, AMR causes 25,000 deaths every year; two thirds of these are due to Gram-negative bacteria.
AMR will result in 1.5 billion EUR extra healthcare costs and productivity losses across Europe, based on 2007 estimates.
There are an estimated 1 billion cases of influenza each year worldwide.
Each year there are around 300,000-500,000 deaths due to influenza worldwide.
What we've been working on
RECLAIM was a Phase 3 trial that recently concluded and evaluated the safety and efficacy of ceftazidime-avibactum (CAZ-AVI) in patients with complicated intra-abdominal infections.
COVERS was a Phase 3 trial evaluating the safety and efficacy of ceftaroline fosamil in patients with complicated skin and soft tissue infection (cSSTI) versus vancomycin plus aztreonam.
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.
Infection, Neuroscience and Gastrointestinal (as at 28 July 2016)
Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.
AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season
AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan
Positive Phase III results demonstrate efficacy of antibiotic medicine CAZ-AVI in complicated Urinary Tract Infections
Events and talks
The key upcoming conferences and events to key an eye on in Infection & Vaccines
We have no upcoming events at the moment. Please look again soon as events will be added nearer to the time.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
Page Atlas ID: 958857.011
Date of next review: March 2017